Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract

Journal of Molecular Biology

Volumn 368, Issue 3, 2007, Pages 652-665

  Wu, Herren ^a   Pfarr, David S ^a   Johnson, Syd ^a   Brewah, Yambasu A ^a   Woods, Robert M ^a   Patel, Nita K ^a   White, Wendy I ^a   Young, James F ^a   Kiener, Peter A ^a  

^a MEDIMMUNE   (United States)

Author keywords

affinity maturation; antibody engineering; motavizumab; palivizumab; respiratory syncytial virus

Indexed keywords

ANTIVIRUS AGENT; MOTAVIZUMAB; PALIVIZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG POTENCY; GENE MUTATION; GENE SEQUENCE; LOWER RESPIRATORY TRACT INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; RAT; RECEPTOR BINDING; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; UPPER RESPIRATORY TRACT INFECTION; VIRUS REPLICATION;

RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS; SIGMODON;

EID: 34047143155     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2007.02.024     Document Type: Article

References (28)

1. Collins P.L., McIntosh K., and Chanock R.M. Respiratory syncytial virus. In: Fields B.N., et al. (Ed). Fields Virology. 3rd edit. (1996), Lippincott-Raven Publishers, Philadelphia, PA 1313-1351
2. Shay D.K., Holman R.C., Newman R.D., Liu L.L., Stout J.W., and Anderson L.J. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282 (1999) 1440-1446
3. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., and Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289 (2003) 179-186
4. Collins P.L., Chanock R.M., and Murphy B.R. Respiratory syncytial virus. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., and Straus S.E. (Eds). Fields Virology. 4th edit. (2001), Lippincott Williams and Wilkins, Philadelphia, PA 1443-1485
5. Beeler J.A., and Coelingh K.V.W. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J. Virol. 63 (1989) 2941-2950
6. Johnson S., Oliver C., Prince G.A., Hemming V.G., Pfarr D.S., Wang S.-C., et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176 (1997) 1215-1224
7. Wu H., Pfarr D.S., Tang Y., An L.-L., Patel N.K., Watkins J.D., et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J. Mol. Biol. 350 (2005) 126-144
8. Byrd L.G., and Prince G.A. Animal models of respiratory syncytial virus infection. Clin. Infect. Dis. 25 (1997) 1363-1368
9. Saez-Llorens X., Moreno M.T., Ramilo O., Sanchez P.J., Top Jr. F.H., and Connor E.M. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. MEDI-493 Study Group. Pediatr. Infect. Dis. J. 23 (2004) 707-712
10. Subramanian K.N., Weisman L.E., Rhodes T., Ariagno R., Sanchez P.J., Steichen J., et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr. Infect. Dis. J. 17 (1998) 110-115
11. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102 (1998) 531-537
12. Chowdhury P.S., and Wu H. Tailor-made antibody therapeutics. Methods 36 (2005) 11-24
13. Malley R., DeVincenzo J., Ramilo O., Dennehy P.H., Meissner H.C., Gruber W.C., et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis. 178 (1998) 1555-1561
14. Busse W.W. Respiratory infections: their role in airway responsiveness and the pathogenesis of asthma. J. Allergy Clin. Immunol. 85 (1990) 671-683
15. Kalina W.V., and Gershwin L.J. Progress in defining the role of RSV in allergy and asthma: from clinical observations to animal models. Clin. Dev. Immunol. 11 (2004) 113-119
16. Rodriguez W.J. Management strategies for respiratory syncytial virus infections in infants. J. Pediatr. 135 (1999) 45-50
17. Hall C.B., McBride J.T., Walsh E.E., Bell D.M., Gala C.L., Hildreth S., et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N. Engl. J. Med. 308 (1983) 1443-1447
18. Randolph A.G., and Wang E.E. Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview. Arch. Pediatr. Adolesc. Med. 150 (1996) 942-947
19. Ventre K., and Randolph A. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst. Rev. 18 (2004) CD000181
20. Hemming V.G., Rodriguez W., Kim H.W., Brandt C.D., Parrott R.H., Burch B., et al. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children. Antimicrob. Agents Chemother. 31 (1987) 1882-1886
21. Rodriguez W.J., Gruber W.C., Groothuis J.R., Simoes E.A., Rosas A.J., Lepow M., et al. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics 100 (1997) 937-942
22. Rodriguez W.J., Gruber W.C., Welliver R.C., Groothuis J.R., Simoes E.A., Meissner H.C., et al. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections. Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics 99 (1997) 454-461
23. Haynes L.M., Tonkin J., Anderson L.J., and Tripp R.A. Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection. J. Virol. 76 (2002) 6873-6881
24. Ottolini M.G., Curtis S.J., Porter D.D., Mathews A., Richardson J.Y., Hemming V.G., and Prince G.A. Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats. Antimicrob. Agents Chemother. 46 (2002) 2299-2302
25. Prince G.A., Mathews A., Curtis S.J., and Porter D.D. Treatment of respiratory syncytial virus bronchiolitis and pneumonia in a cotton rat model with systemically administered monoclonal antibody (palivizumab) and glucocorticosteroid. J. Infect. Dis. 182 (2000) 1326-1330
26. Wathen M.W., Brideau R.J., and Thomsen D.R. Immunization of cotton rats with the human respiratory syncytial virus F glycoprotein produced using a baculovirus vector. J. Infect. Dis. 159 (1989) 255-264
27. Kabat E.A., Wu T.T., Perry H.M., Gottesman K.S., and Foeller C. Sequences of Proteins of Immunological Interest (1991), U.S. Department of Health and Human Services, Washington, DC
28. Johnsson B., Lofas S., and Lindquist G. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal. Biochem. 198 (1991) 268-277